PDCD1 and neoplasm: Compared to the control treatment, the combination treatment of paclitaxel (PTX) + anti-CTLA-4 antibody + anti-PD-1 antibody inhibited tumor cell proliferation, improved CD4+ T cell proliferation, reduced hypoxia, with notable improvements in vascular distribution and significant increases in IL-2, IL-4, and IL-12 levels.